Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan

Farah Naz Qamar, Mohammad Tahir Yousafzai, Asif Khaliq, Sultan Karim, Hina Memon, Amber Junejo, Inayat Baig, Najeeb Rahman, Shafqat Bhurgry, Hina Afroz, Uzma Sami, Farah Naz Qamar, Mohammad Tahir Yousafzai, Asif Khaliq, Sultan Karim, Hina Memon, Amber Junejo, Inayat Baig, Najeeb Rahman, Shafqat Bhurgry, Hina Afroz, Uzma Sami

Abstract

Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.

Keywords: AEFI; Adverse events; Campaign; Salmonella Typhi; Typbar-TCV; Vaccination.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
TCV vaccination and follow-up among vaccinated children.
Fig. 2
Fig. 2
Age stratified AEFI rates reported through active follow up or self-reported by the parents though hotline.

References

    1. Dewan A.M., Corner R., Hashizume M., Ongee E.E. Typhoid fever and its association with environmental factors in the Dhaka metropolitan area of Bangladesh: a spatial and time-series approach. PLoS Negl Trop Dis. 2013;7
    1. Kim J.-H., Im J., Parajulee P., Holm M., Cruz Espinoza L.M., Poudyal N. A systematic review of typhoid fever occurrence in Africa. Clin Infect Dis. 2019;69:S492–S498.
    1. GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19:369-81.
    1. World Health Organization. ANTIMICROBIAL RESISTANCE Global Report on Surveillance 2014.
    1. Browne A.J., Kashef Hamadani B.H., Kumaran E.A.P., Rao P., Longbottom J., Harriss E. Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis. BMC Med. 2020;18:1.
    1. Qamar F.N., Yousafzai M.T., Sultana S., Baig A., Shakoor S., Hirani F. A retrospective study of laboratory-based enteric fever surveillance, Pakistan, 2012–2014. J Infect Dis. 2018;218:S201–S205.
    1. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an Extensively Drug-Resistant Salmonella enterica Serovar Typhi Clone Harboring a Promiscuous Plasmid Encoding Resistance to Fluoroquinolones and Third-Generation Cephalosporins. mBio. 2018;9.
    1. Yousafzai M.T., Qamar F.N., Shakoor S., Saleem K., Lohana H., Karim S. Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: high time for the introduction of typhoid conjugate vaccine. Clin Infect Dis. 2019;68:S16–S21.
    1. Qamar F.N., Yousafzai M.T., Khalid M., Kazi A.M., Lohana H., Karim S. Outbreak investigation of ceftriaxone-resistant Salmonella enterica serotype Typhi and its risk factors among the general population in Hyderabad, Pakistan: a matched case-control study. Lancet Infect Dis. 2018;18:1368–1376.
    1. Andrews J.R., Qamar F.N., Charles R.C., Ryan E.T. Extensively drug-resistant typhoid - are conjugate vaccines arriving just in time? N Engl J Med. 2018;379:1493–1495.
    1. World Health Organization. Typbar TCV® from Bharat Biotech, World’s First Typhoid Conjugate Vaccine Prequalified by WHO World Health Organization; 3rd January 2018.
    1. World Health Organization Typhoid vaccines: WHO position paper, March 2018 – Recommendations. Vaccine. 2019;37:214–216.
    1. Shakya M., Colin-Jones R., Theiss-Nyland K., Voysey M., Pant D., Smith N. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. N Engl J Med. 2019;381:2209–2218.
    1. Mohan V.K., Varanasi V., Singh A., Pasetti M.F., Levine M.M., Venkatesan R. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis. 2015;61:393–402.
    1. Jin C., Gibani M.M., Moore M., Juel H.B., Jones E., Meiring J. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472–2480.
    1. Pakistan Bureau of Statistics. 6th Population and housing census - 2017. Pakistan2017.
    1. Kohl K.S., Bonhoeffer J., Braun M.M., Chen R.T., Duclos P., Heijbel H. The Brighton Collaboration: creating a global standard for case definitions (and guidelines) for adverse events following immunization. Advances in patient safety: from research to implementation (volume 2: concepts and methodology): Agency for. Healthcare Res Quality (US) 2005
    1. Liu D., Wu W., Li K., Xu D., Ye J., Li L. Surveillance of adverse events following immunization in China: Past, present, and future. Vaccine. 2015;33:4041–4046.
    1. Mitra M., Shah N., Ghosh A., Chatterjee S., Kaur I., Bhattacharya N. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph) in Indian children: School based cluster randomized study. Hum Vaccin Immunother. 2016;12:939–945.
    1. Capeding M.R., Teshome S., Saluja T., Syed K.A., Kim D.R., Park J.Y. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. Vaccine. 2018;36:3794–3801.
    1. Capeding M.R., Alberto E., Sil A., Saluja T., Teshome S., Kim D.R. Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: a preliminary report. Vaccine. 2019
    1. National Institute of Population Studies . National Institute of Population Studies; Islamabad, Pakistan: 2019. Paksitan demographic and health survey 2017–18.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera